GW Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 05/5/2021)
Today's Range
50-Day Range
52-Week Range
Average Volume899,771 shs
Market Capitalization$6.86 billion
P/E RatioN/A
Dividend YieldN/A

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GW Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GW Pharmaceuticals logo

About GW Pharmaceuticals

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.29 out of 5 stars

Medical Sector

883rd out of 2,100 stocks

Pharmaceutical Preparations Industry

428th out of 831 stocks

Analyst Opinion: 1.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions

Is GW Pharmaceuticals a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals in the last year. There are currently 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GW Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GWPH, but not buy additional shares or sell existing shares.
View analyst ratings for GW Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than GW Pharmaceuticals?

Wall Street analysts have given GW Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GW Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is GW Pharmaceuticals' next earnings date?

GW Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for GW Pharmaceuticals

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals plc (NASDAQ:GWPH) posted its earnings results on Friday, April, 30th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.57. The biopharmaceutical company had revenue of $152.47 million for the quarter, compared to the consensus estimate of $157.15 million. GW Pharmaceuticals had a negative net margin of 11.05% and a negative trailing twelve-month return on equity of 7.46%.
View GW Pharmaceuticals' earnings history

What price target have analysts set for GWPH?

14 brokerages have issued 1 year target prices for GW Pharmaceuticals' shares. Their forecasts range from $140.00 to $275.00. On average, they anticipate GW Pharmaceuticals' stock price to reach $204.09 in the next year. This suggests that the stock has a possible downside of 6.8%.
View analysts' price targets for GW Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are GW Pharmaceuticals' key executives?

GW Pharmaceuticals' management team includes the following people:
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 50, Pay $1.19M)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 51, Pay $743.33k)
  • Mr. Douglas B. Snyder, Chief Legal Officer & Sec. (Age 57, Pay $787.02k)
  • Dr. Volker Knappertz M.D., D.Sc., Chief Medical Officer (Age 56, Pay $830.47k)
  • Mr. Christopher John Tovey, Chief Operating Officer (Age 56)
  • Kristen Cardillo, VP of Corp. Communication
  • Ms. Tina St. Leger, Chief HR Officer
  • Prof. Ben Whalley, Head of Discovery Research
  • Mr. Darren S. Cline, U.S. Chief Commercial Officer (Age 57)

What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?

14 employees have rated GW Pharmaceuticals CEO Justin Gover on Justin Gover has an approval rating of 80% among GW Pharmaceuticals' employees.

Who are some of GW Pharmaceuticals' key competitors?

What other stocks do shareholders of GW Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Intel (INTC), Netflix (NFLX), Gilead Sciences (GILD), Aurora Cannabis (ACB) and Advanced Micro Devices (AMD).

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."

Who are GW Pharmaceuticals' major shareholders?

GW Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pentwater Capital Management LP (6.71%), Alpine Associates Management Inc. (2.51%), Morgan Stanley (2.09%), TIG Advisors LLC (1.83%), Janus Henderson Group PLC (1.45%) and Brown Capital Management LLC (1.44%). Company insiders that own GW Pharmaceuticals stock include Adam D George, Cabot Brown, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave.
View institutional ownership trends for GW Pharmaceuticals

Which institutional investors are selling GW Pharmaceuticals stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Janus Henderson Group PLC, Federated Hermes Inc., Bellevue Group AG, Bank of New York Mellon Corp, M&G Investment Management Ltd., Morgan Stanley, and Roosevelt Investment Group LLC. Company insiders that have sold GW Pharmaceuticals company stock in the last year include Adam D George, Cabot Brown, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, and Volker Knappertz.
View insider buying and selling activity for GW Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying GW Pharmaceuticals stock?

GWPH stock was bought by a variety of institutional investors in the last quarter, including Pentwater Capital Management LP, Alpine Associates Management Inc., TIG Advisors LLC, Omni Partners LLP, JPMorgan Chase & Co., Spring Creek Capital LLC, Grantham Mayo Van Otterloo & Co. LLC, and Carlson Capital L P.
View insider buying and selling activity for GW Pharmaceuticals
or or view top insider-buying stocks.

What is GW Pharmaceuticals' stock price today?

One share of GWPH stock can currently be purchased for approximately $218.96.

How much money does GW Pharmaceuticals make?

GW Pharmaceuticals has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does GW Pharmaceuticals have?

GW Pharmaceuticals employs 1,161 workers across the globe.

What is GW Pharmaceuticals' official website?

The official website for GW Pharmaceuticals is

Where are GW Pharmaceuticals' headquarters?

GW Pharmaceuticals is headquartered at SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ.

How can I contact GW Pharmaceuticals?

GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.